Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC
Status:
NOT_YET_RECRUITING
Trial end date:
2029-07-30
Target enrollment:
Participant gender:
Summary
This study is aimed to evaluate the efficacy and safety of Sacituzumab Tirumotecan combined with Toripalimab for first-line treatment of PD-L1 positive unresectable Locally Advanced/metastatic triple negative breast cancer (a/mTNBC).
Phase:
PHASE2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital